Showing results (141-150 of 208) with videos related to
Sort By:
Pageof 21
Clinical and Translational Science|February 16, 2024
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumorsDebbie Robbrecht, Jean-Jacques Grob, Oliver Bechter, et al.European Journal of Cancer (Oxford, England : 1990)|May 17, 2019
Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)Celeste Lebbe, Claus Garbe, Alexander J Stratigos, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2023
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 TrialPaolo Antonio Ascierto, Evan J Lipson, Reinhard Dummer, et al.European Journal of Cancer (Oxford, England : 1990)|January 14, 2020
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019Claus Garbe, Teresa Amaral, Ketty Peris, et al.JAMA Dermatology|July 16, 2020
Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic MelanomaAngélique Brunot, Jean-Jacques Grob, Geraldine Jeudy, et al.European Journal of Cancer (Oxford, England : 1990)|July 10, 2019
Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelinesKetty Peris, Maria Concetta Fargnoli, Claus Garbe, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2023
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401Reinhard Dummer, Pippa Corrie, Ralf Gutzmer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2024
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 StudyJason J Luke, Paolo A Ascierto, Muhammad A Khattak, et al.European Journal of Cancer (Oxford, England : 1990)|March 22, 2015
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanomaDirk Schadendorf, Mayur M Amonkar, Daniil Stroyakovskiy, et al.The New England Journal of Medicine|January 5, 2022
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced MelanomaHussein A Tawbi, Dirk Schadendorf, Evan J Lipson, et al.Pageof 21